Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 704 Print this page  Email this page Small font size Default font size Increase font size
Year : 2014  |  Volume : 29  |  Issue : 2  |  Page : 65-73

FLT PET-CT in evaluation of treatment response

1 Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, England
2 Cancer Centre, Mount Vernon Hospital, Northwood, England
3 Cancer Centre, Mount Vernon Hospital, Northwood; Department of Haematology, University College London Cancer Institute and University College Hospital, London, England

Correspondence Address:
Bal Sanghera
Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, HA6 2RN
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-3919.130274

Rights and Permissions

Purpose: Review published studies to investigate the value of clinical 3-deoxy-3- 18 F-fluorothymidine (FLT) positron emission tomography (PET) in predicting response to treatment. Materials and Methods: Interrogate databases to identify suitable publications between 2007 and 2013 with a minimum of five patients. Articles within the inclusion criteria were reviewed with major findings reported leading to a descriptive analysis of FLT PET in therapy response. Results: Lesions investigated included glioma, head and neck, esophageal, lung, breast, gastric, renal, rectal, sarcomas, germ cell, lymphomas, leukemia, and melanoma resulting in a total of 34 studies analyzed. A variety of therapies were applied and dissimilar PET protocols were widespread making direct comparison between studies challenging. Though baseline, early and late therapy scans were popular particularly in chemotherapy regimes. Most studies investigated showed significantly reduced FLT uptake during or after therapy compared with pretreatment scans. Conclusion: Current evidence suggests FLT PET has a positive role to play in predicting therapy response especially in brain, lung, and breast cancers where good correlation with Ki-67 is observed. However, careful attention must be placed in undertaking larger clinical trials where harmonization of scanning and analysis protocols are strictly adhered to fully assess the true potential of FLT PET in predicting response to treatment.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded383    
    Comments [Add]    
    Cited by others 9    

Recommend this journal